Denovan-Wright EM - Search Results

1

Neurodevelopmental and genetic determinants of exposure to adversity among youth at risk for mental illness.

Zwicker A, MacKenzie LE, Drobinin V, Bagher AM, Howes Vallis E, Propper L, Bagnell A, Abidi S, Pavlova B, Alda M, Denovan-Wright EM, Uher R. Zwicker A, et al. J Child Psychol Psychiatry. 2020 May;61(5):536-544. doi: 10.1111/jcpp.13159. Epub 2019 Nov 20. J Child Psychol Psychiatry. 2020. PMID: 31749149

2

Co-expression of the human cannabinoid receptor coding region splice variants (hCB₁) affects the function of hCB₁ receptor complexes.

Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM. Bagher AM, et al. Eur J Pharmacol. 2013 Dec 5;721(1-3):341-54. doi: 10.1016/j.ejphar.2013.09.002. Epub 2013 Oct 1. Eur J Pharmacol. 2013. PMID: 24091169

3

Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature.

MacIntyre J, Dong A, Straiker A, Zhu J, Howlett SE, Bagher A, Denovan-Wright E, Yu DY, Kelly ME. MacIntyre J, et al. Eur J Pharmacol. 2014 Jul 15;735:105-14. doi: 10.1016/j.ejphar.2014.03.055. Epub 2014 Apr 18. Eur J Pharmacol. 2014. PMID: 24751709

4

Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.

Laprairie RB, Bagher AM, Kelly ME, Dupré DJ, Denovan-Wright EM. Laprairie RB, et al. J Biol Chem. 2014 Sep 5;289(36):24845-62. doi: 10.1074/jbc.M114.557025. Epub 2014 Jul 18. J Biol Chem. 2014. PMID: 25037227 Free PMC article.

5

Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.

Laprairie RB, Bagher AM, Precious SV, Denovan-Wright EM. Laprairie RB, et al. Pharmacol Res Perspect. 2015 Feb;3(1):e00104. doi: 10.1002/prp2.104. Epub 2015 Jan 5. Pharmacol Res Perspect. 2015. PMID: 25692022 Free PMC article.

6

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Laprairie RB, et al. Br J Pharmacol. 2015 Oct;172(20):4790-805. doi: 10.1111/bph.13250. Epub 2015 Oct 13. Br J Pharmacol. 2015. PMID: 26218440 Free PMC article.

7

Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Laprairie RB, et al. Mol Pharmacol. 2016 Mar;89(3):364-75. doi: 10.1124/mol.115.101980. Epub 2015 Dec 23. Mol Pharmacol. 2016. PMID: 26700564

8

Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.

Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM. Bagher AM, et al. Mol Pharmacol. 2016 Jun;89(6):652-66. doi: 10.1124/mol.116.103465. Epub 2016 Apr 6. Mol Pharmacol. 2016. PMID: 27053685

9

Cannabinoid receptor ligand bias: implications in the central nervous system.

Laprairie RB, Bagher AM, Denovan-Wright EM. Laprairie RB, et al. Curr Opin Pharmacol. 2017 Feb;32:32-43. doi: 10.1016/j.coph.2016.10.005. Epub 2016 Nov 9. Curr Opin Pharmacol. 2017. PMID: 27835801 Review.

10

Bidirectional allosteric interactions between cannabinoid receptor 1 (CB₁) and dopamine receptor 2 long (D_2L) heterotetramers.

Bagher AM, Laprairie RB, Toguri JT, Kelly MEM, Denovan-Wright EM. Bagher AM, et al. Eur J Pharmacol. 2017 Oct 15;813:66-83. doi: 10.1016/j.ejphar.2017.07.034. Epub 2017 Jul 19. Eur J Pharmacol. 2017. PMID: 28734930

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

98 results

Search Page

Filters